Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai rolls out breast cancer drug in Japan
The US Food and Drug Administration approved Halaven is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens
The US Food and Drug Administration approved Halaven is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens
Sanofi Pasteur, the vaccine division of Sanofi-aventis, intends to ship around 70 million doses of influenza vaccine for this season. The company expects to offer two formulations of
Under the agreement, Hitachi will offer Cegedim’s Mobile Intelligence solution to its clients. Hitachi will provide Mobile Intelligence solution initially in Japan and intends to offer in several
The FDA approval was given on the basis of the results from a six-month study, which demonstrated that the drug is safe and effective in maintaining endoscopic remission
The company has reported a net income of $258.14m, or $0.90 per diluted share, compared to net income of $117.48m or $0.39 per diluted share, for the same
Procort, formulated by Skinvisible’s patented polymer delivery system Invisicare, is a kind of topical steroid that helps in reducing swelling, redness, allergic reactions and itching. Earlier, Skinvisible has
Most recently, Barr worked as the chief operating officer and executive vice president of Covance. Before Covance, he worked with Marconi Medical Systems as the vice president and
Ohio-based ATI is a privately held company that specializes in microencapsulation, liquid crystal thermometers and temperature indicating devices for the pharmaceutical, medical device and food markets. By including
According to the company, the kit uses zinc finger nucleases (ZFNs) for heritable gene knockin at the target locus (Rosa26 or AAVS1). Sigma Life Science has also launched
Sapacitabine is in Phase 3 development for the treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes and lung cancer. According to